Literature DB >> 18613411

Factors associated with natural seroclearance of hepatitis B surface antigen and prognosis after seroclearance: a prospective follow-up study.

Jeong Hwan Kim1, Joon Hyoek Lee, Sang Jong Park, Mun Hee Bae, Ji Hyang Kim, Do Young Kim, Jong Kyu Kim, Moon Seok Choi, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo.   

Abstract

BACKGROUND/AIMS: Although the natural seroclearance rate of Hepatitis B surface antigen (HBsAg) is reported to be 0.4-2% in western countries, this is not well known in Korea. This study aimed to elucidate the rate of natural HbsAg seroclearance, factors associated with seroclearance and prognosis after seroclearance.
METHODOLOGY: In 1999, 250 chronic HBsAg carriers without any history of antiviral treatment and without any evidence of liver cirrhosis or hepatocellular carcinoma were selected. Follow-up HBsAg/ anti-HBs tests were performed annually till 2004. During a mean follow-up period of 48 months, 24 patients were lost and 11 received antiviral treatment. Finally, 215 patients completed the study.
RESULTS: HBsAg seroclearance was observed in 11 patients (6 males, 5 females). One-year seroclearance rate was 1.4%. All patients who achieved seroclearance were HBeAg (-)/HBV DNA (-) at the time of enrollment. Additionally, old age and normal serum alanine aminotransferase (ALT) level were the factors associated with seroclearance (p < 0.05, respectively). During the follow-up period, only mild transient elevations of ALT were observed in 4 patients and no serious complications were observed.
CONCLUSIONS: Natural seroclearance occurred exclusively in patients who were HBeAg (-)/HBV-DNA (-), and annual rate of natural HBsAg seroclearance was 1.4%. No significant complications were observed after seroclearance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18613411

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  12 in total

1.  Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses.

Authors:  Kali Zhou; Caitlin Contag; Evans Whitaker; Norah Terrault
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-01-22

2.  HBsAg loss in a New Zealand community study with 28-year follow-up: rates, predictors and long-term outcomes.

Authors:  Tien Huey Lim; Edward Gane; Chris Moyes; Barry Borman; Chris Cunningham
Journal:  Hepatol Int       Date:  2016-03-08       Impact factor: 6.047

3.  Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up.

Authors:  Mariko Kobayashi; Tetsuya Hosaka; Fumitaka Suzuki; Norio Akuta; Hitomi Sezaki; Yoshiyuki Suzuki; Yusuke Kawamura; Masahiro Kobayashi; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Yuzo Miyakawa; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2013-06-20       Impact factor: 7.527

4.  Estimating age-related incidence of HBsAg seroclearance in chronic hepatitis B virus infections of China by using a dynamic compartmental model.

Authors:  Jian Zu; Guihua Zhuang; Peifeng Liang; Fuqiang Cui; Fuzhen Wang; Hui Zheng; Xiaofeng Liang
Journal:  Sci Rep       Date:  2017-06-06       Impact factor: 4.379

Review 5.  Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog.

Authors:  Tai-Chung Tseng; Jia-Horng Kao
Journal:  J Gastroenterol       Date:  2012-10-24       Impact factor: 7.527

6.  Host genetic factors affecting spontaneous HBsAg seroclearance in chronic hepatitis B patients.

Authors:  Huei-Ru Cheng; Chun-Jen Liu; Tai-Chung Tseng; Tung-Hung Su; Hwai-I Yang; Chien-Jen Chen; Jia-Horng Kao
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

7.  Time to seroconversion of HBsAg to anti-HBs in individuals who lost HBsAg during follow-up.

Authors:  M R H Roushan; M Mohammadpour; M Baiany; S Soleimani; A Bijani
Journal:  Epidemiol Infect       Date:  2016-06-08       Impact factor: 4.434

8.  Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative.

Authors:  Dengming He; Shimin Guo; Wen Chen; Xianli Chen; Guohua Yan; Jie Wang; Maoshi Li; Peng Zhu; Hongfei Huang; Yuming Wang
Journal:  BMC Infect Dis       Date:  2013-10-03       Impact factor: 3.090

Review 9.  Large variations in risk of hepatocellular carcinoma and mortality in treatment naïve hepatitis B patients: systematic review with meta-analyses.

Authors:  Maja Thiele; Lise Lotte Gluud; Annette Dam Fialla; Emilie Kirstine Dahl; Aleksander Krag
Journal:  PLoS One       Date:  2014-09-16       Impact factor: 3.240

10.  Seroclearance of Hbsag in Chronic Hepatitis B Virus Patients on Lamivudine Therapy: A 10 Year Experience.

Authors:  Shahnaz Sali; Muayad A Merza; Sina Saadat; Nazik H Mustafa; Farzam Queiky; Davood Yadegarynia
Journal:  Glob J Health Sci       Date:  2015-04-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.